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Purpose: We conducted a prospective study in patients with normal-tension glaucoma 
(NTG) who received either isopropyl unoprostone or latanoprost. We compared the drugs in 
terms of their effects on intraocular pressure (IOP) and visual field loss progression over a 
3-year period.
Study design: Prospective, randomized controlled study.
Methods: We enrolled 48 patients with newly diagnosed NTG at Kanazawa University Hospital. 
Eligible patients were randomly allocated (1:1) to receive either unoprostone or latanoprost 
ophthalmic solutions. The primary outcomes were IOP changes and visual field deterioration 
within 36 months. Visual field changes were analyzed: the cumulative survival rates were cal-
culated in terms of mean deviation, pattern standard deviation, and total deviation of the upper 
or lower hemi-visual field, each visual field sector, and guided progression analysis. In addition, 
we evaluated the progression of glaucomatous optic disc changes using fundus photography 
and confocal scanning laser ophthalmoscopy.
Results: The mean pretreatment IOP was 15.0±2.4 mmHg in the Unoprostone group and 
15.2±1.9 mmHg in the Latanoprost group. The mean IOP during the treatment period was 
13.7±2.3 mmHg in the Unoprostone group and 13.0±1.8 mmHg in the Latanoprost group. 
In both groups, the IOP decreased significantly (p0.001) from baseline after treatment. 
The posttreatment IOP values were significantly lower in the Latanoprost group than in the 
Unoprostone group (p=0.023). Regarding the 3-year cumulative survival rate of visual field 
loss progression, there were no significant differences between groups in any parameters of 
the visual field or guided progression analysis. There were no significant differences between 
groups in disc changes.
Conclusions: No significant differences were found between groups with regard to the visual 
field and structural progression in patients with NTG, although unoprostone was less effective 
than latanoprost in lowering the IOP.
Keywords: unoprostone, latanoprost, normal-tension glaucoma, intraocular pressure, 
visual field
Introduction
Lowering the intraocular pressure (IOP) is the only evidence-based therapy to delay 
visual field deterioration in patients with glaucoma.1,2 To evaluate the efficacy of 
various glaucoma drugs, a long-term comparative study is necessary. Latanoprost 
(Xalatan®; Pfizer Co., Ltd, Tokyo, Japan) has been reported to prevent progressive 
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visual field loss with a strong IOP-lowering effect.3 Saito et al 
reported that isopropyl unoprostone (unoprostone: Rescula®; 
R-Tech Ueno Ltd., Tokyo, Japan) prevented visual field loss 
progression in patients with primary open-angle glaucoma 
(POAG), including normal-tension glaucoma (NTG),4 
although unoprostone was less effective than latanoprost in 
lowering the IOP.5–9
Recently, the role of unoprostone was demonstrated to 
be different from that of other prostaglandin-related drugs. 
On the basis of its pharmacological characteristics, unopro-
stone was characterized as an ion-channel opener10,11 and 
was associated with an increase in conventional outflow,12 
improvement of microcirculatory blood flow, and a neuro-
protective action.13,14
We conducted a prospective, randomized controlled study 
in patients with NTG. The patients received either unopros-
tone or latanoprost, and we compared the drugs in terms of 
their effects on IOP and visual field loss progression over a 
period of 3 years.
Methods
subjects
Treatment-naïve patients with NTG were enrolled at the 
Department of Ophthalmology in Kanazawa University 
Hospital between March 2004 and April 2009. The inclusion 
criteria were 1) visual field mean deviation (MD) of −10 dB 
or better by standard automated perimetry (Humphrey Visual 
Field Analyzer II, 30–2 Swedish interactive threshold 
algorithm, Carl Zeiss Meditec, Inc, Dublin, CA), 2) best-
corrected visual acuity of 0.7 or more, 3) spherical equiva-
lent refractive error between −10 D and 10 D, and 4) age of 
20 years or more. Only one eye from each patient was included 
in the trial. If both eyes from the same patient were eligible, 
data from the eye with the lower MD were used for analysis. 
The exclusion criteria were 1) ocular infection, inflammatory 
disease, or corneal ulcer that occurred 1 month before the 
start of the trial, 2) cataract, retinal disorder, or other disorder 
that may affect the visual field, 3) history of ocular surgery 
or laser treatment, 4) optic nerve degeneration other than 
glaucoma, and 5) pregnancy or suspected pregnancy.
NTG was defined as involving the following: 1) normal 
open angle, 2) retinal nerve fiber layer defect, or characteristic 
thinning of the optic disc rim on fundus photographs (includ-
ing red-free photos) with corresponding visual field defects, 
3) no ocular or systemic disorder responsible for a visual field 
defect, and 4) an untreated IOP of 21 mmHg or less.
This study was approved by the Institutional Review 
Board (IRB) of Kanazawa University, and the study was 
conducted in full accord with the tenets of the Declaration 
of Helsinki. Written informed consent was obtained from 
all patients before screening investigations, and potential 
adverse effects were fully explained.
study groups
The subjects were randomly assigned (1:1), with the closed 
envelope technique, to receive either isopropyl unoprostone 
eye drops (Rescula; 0.12%, 1 drop twice daily – morning 
and evening – the Unoprostone group) or latanoprost eye 
drops (Xalatan, 0.005%, 1 drop once daily – evening – the 
Latanoprost group). The concomitant use of drugs that may 
have affected glaucoma (topical/systemic anti-glaucoma 
drugs or topical/systemic steroids) was not permitted dur-
ing the study.
study protocol
The subjects were examined twice before starting treatment 
and every 3 months thereafter. At each examination, any 
subject who had forgotten to instill the eye drops on 10% of 
the days during the previous 3 months was excluded from the 
study. Adherence to the treatment was based on a statement 
provided by the patient. IOP was measured every 3 months in 
a masked fashion with a Goldmann applanation tonometer. 
The ophthalmologist who measured the IOP was blinded to 
the drug used. Standard automated perimetry was performed 
twice before treatment and every 6 months thereafter. Visual 
acuity was assessed every 12 months. The optic nerve head 
was imaged every 12 months with a fundus camera (Kowa 
nonmyd WX3D retinal camera; Kowa Co., Tokyo, Japan) 
and a confocal scanning laser ophthalmoscope (Heidelberg 
Retina Tomograph II [HRT-II]; Heidelberg Engineering 
GmbH, Heidelberg, Germany). These examinations were per-
formed by an examiner who was blinded to the drug used.
Topical administration was discontinued or changed if 
adverse effects or a serious eye disease occurred or if there 
was a request by the subject or a decision by the investigator, 
considering various factors including the progression of 
visual field defects.
Main outcome measures
The main outcome measures were IOP reduction and visual 
field progression after treatment.
evaluation of structural changes in the 
optic nerve head
Three glaucoma specialists compared the pair of fundus 
photographs taken at baseline and 36 months after treatment 
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initiation, which were projected onto a screen alternatively 
and repeatedly. The chronological order of the two photos was 
masked. Structural progression was defined as the presence of 
increased rim thinning, enlarged cupping, or enlargement or 
emergence of retinal nerve fiber layer defects. Progression was 
judged to be positive when the decision was agreed upon by 
all three graders and the chronological order was correct.
Secondly, stereometric parameters of HRT-II, cup area 
(mm2), rim area (mm2), cup area/disc area ratio, cup volume 
(mm3), and rim volume (mm3) were examined. The HRT 
images with an SD of topography of 50 μm or less were 
adopted.
statistical analysis
The mean posttreatment IOP was compared with the base-
line IOP by paired t-test in each group. The mean percentage 
IOP reduction after treatment was compared between groups 
with the Mann–Whitney U test.
Visual field loss progression was judged to have reached 
its end point relative to baseline when all of the follow-
ing conditions were fulfilled: 1) MD deterioration 3 dB 
demonstrated twice during the follow-up period compared 
with the two baseline values (defined as “MD criteria”), 
2) pattern standard deviation (PSD) deterioration 3 dB 
demonstrated twice during the follow-up period compared 
with the two baseline values (defined as “PSD criteria”), 
3) total deviation (TD) of the upper or lower hemi-visual field 
deterioration 3 dB demonstrated twice during the follow-up 
period compared with the two baseline values (defined as 
“hemi-visual field TD criteria”), 4) when guided progression 
analysis (GPA) was applicable, the time of either “possible 
progression” or “highly possible progression”, 5) TD in each 
sector of a Garway–Heath sector format15 deteriorated 3 dB 
twice during the follow-up period compared with the two 
baseline values. Dropout for any reason, including visual 
acuity decrease (0.7), adverse reactions, alteration of 
unoprostone or latanoprost treatment, or addition of another 
medication, was treated as a treatment failure in each set of 
criteria. The cumulative probability of survival was compared 
between groups with the Kaplan–Meier method (log-rank 
test) for each set of end point criteria listed above.
The number of dropouts and the number of eyes with 
optic disc progression were compared between groups with 
Fisher’s exact probability test.
Stereometric parameters of HRT-II were compared 
between groups with Mann–Whitney U test.
SPSS statistical software, version 17.0J for Windows 
(SPSS, Inc., Chicago, IL, USA), was used for analysis, and 
a p-value of 0.05 was considered statistically significant. 
Values are stated as mean ± SD.
Results
A total of 48 eyes from 48 patients were enrolled in this trial. 
The characteristics of the patients in each group are shown 
in Table 1. There were no statistically significant differ-
ences between the Unoprostone (n=24) and the Latanoprost 
(n=24) groups in terms of age, sex, visual acuity, spherical 
equivalent refractive error, pretreatment IOP, MD, PSD, or 
duration of follow-up.
Figure 1 demonstrates the IOP in each group at base-
line and every 3 months after treatment. The pretreatment 
IOP was 15.0±2.4 mmHg in the Unoprostone group and 
15.2±1.9 mmHg in the Latanoprost group. The mean IOP 
during the entire treatment period was 13.7±2.3 mmHg 
in the Unoprostone group and 13.0±1.8 mmHg in the 
Latanoprost group. Thus, the mean percentage IOP reduc-
tion after treatment was 9%±10% in the Unoprostone group 
and 14%±13% in the Latanoprost group. In both groups, the 
mean IOP during the entire treatment period had decreased 
significantly compared with baseline IOP (Unoprostone 
group: p0.001; Latanoprost group: p0.001). The mean 
percentage IOP reduction after treatment was significantly 
greater in the Latanoprost group than in the Unoprostone 
group (p=0.023).
Figures 2 and 3 show the cumulative probability of 
visual field nonprogression in the Unoprostone group and 
the Latanoprost group. The cumulative survival rates after 
3 years were 74% in the Unoprostone group and 80% in the 
Latanoprost group when the end point was defined by MD 
criteria (Figure 2A); 94% in the Unoprostone group and 90% 
Table 1 Baseline patient characteristics
Characteristic UNO group  
(24 patients)
LAT group  
(24 patients)
p-value
age, years 57±12 59±13 0.89a
sex, n (%)
Men 9 (38%) 12 (50%) 0.28b
Women 15 (62%) 12 (50%)
Visual acuity, logMar value 0.012±0.037 0.006±0.022 0.67a
refractive value, diopter −2.4±3.3 −2.6±2.6 0.64a
Pretreatment iOP, mmhg 15.0±2.4 15.2±1.9 0.78a
MD value, dB −3.5±2.7 −3.7±2.9 0.65a
PsD value, dB 6.8±4.2 6.7±3.3 0.88a
Duration of follow-up, months 34±8 32±9 0.62a
Notes: aMann–Whitney U test; bFisher’s exact probability test. Values are mean ± 
sD unless otherwise noted.
Abbreviations: iOP, intraocular pressure; laT, latanoprost; MD, mean deviation; 
PsD, pattern standard deviation; UnO, unoprostone.





in the Latanoprost group by PSD criteria (Figure 2B); 77% 
in the Unoprostone group and 70% in the Latanoprost group 
by hemi-visual field TD criteria (Figure 2C); 67% in the 
Unoprostone group and 49% in the Latanoprost group defined 
by “possible progression” in GPA (Figure 3A); and 94% in 
the Unoprostone group and 75% in the Latanoprost group 
defined by “highly possible progression” in GPA (Figure 3B). 
There were no significant differences between groups in any 
analyses including six sector analyses with regard to the rates 
of visual field nonprogression (Table 2).
In the fundus photograph assessment, 8 (33.3%) eyes 
were classified as having progression, whereas 16 (66.7%) 
eyes were classified as having no progression in both groups 
(p=1.00).
As shown in Table 3, there were no significant differences 
between groups with regard to any of the stereometric param-
eters mentioned above, that is, cup area (mm2), rim area (mm2), 
cup/disc area ratio, cup volume (mm3), or rim volume (mm3).
There were no dropouts due to visual acuity decrease in 
either group during the study. The rate of patient dropout 
is shown in Table 4. There were no significant differences 
between groups in terms of the total number of patient dropouts, 
the number of patient dropouts due to adverse reactions, and 
change of therapy (p=0.50, p=0.30, and p=0.49, respectively). 
































Figure 2 Survival curve of visual field nonprogression.
Notes: (A) The cumulative probability of visual field nonprogression when the end point was defined as the first occurrence of two or more events that caused a 
deterioration in the visual field of −3 dB or worse from the baseline value in terms of MD. (B) The cumulative probability of visual field nonprogression when the end point 
was defined as the first occurrence of two or more events that caused a deterioration in the visual field of −3 dB or worse from the baseline value in terms of PsD. (C) The 
cumulative probability of visual field nonprogression when the end point was defined as the first occurrence of two or more events that caused a deterioration in the visual 
field of −3 dB or worse from baseline in terms of TD of the upper or lower hemi-visual field.
Abbreviations: laT, latanoprost; MD, mean deviation; PsD, pattern standard deviation; TD, total deviation; UnO, unoprostone.






Figure 1 iOP over time.
Notes: iOP in the Unoprostone and the latanoprost treatment groups. iOP 
decreased significantly after treatment, and posttreatment IOP values were 
significantly lower in the LAT group than in the UNO group.
Abbreviations: iOP, intraocular pressure; laT, latanoprost; UnO, unoprostone.
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Two patients in the Unoprostone group were subjected to a 
change in therapy due to visual field progression.
Discussion
Regarding the long-term effects of unoprostone monother-
apy, IOP decreased from 13.7±3.0 mmHg to 12.0±2.2 mmHg 
after 6 years of treatment in patients with NTG.16 Our 
previous study demonstrated that the mean IOP had 
decreased significantly from 14.7±3.0 mmHg at baseline to 
12.7±4.4 mmHg after 4 years in 32 eyes from 32 patients 
with POAG including NTG with unoprostone monotherapy.4 
The 88.0% visual field nonprogression rate for 4 years in the 
study was higher than that in a previous report in untreated 
NTG patients (55.5% nonprogression rate for 4 years).17
Prospective studies that compared the efficacy of uno-
prostone with that of latanoprost for 8 or 12 weeks were 
performed by many investigators.5–8,18 Both unoprostone 
and latanoprost were found to reduce IOP; however, uno-
prostone was less effective than latanoprost in patients 
with either POAG or ocular hypertension. Sponsel et al 
reported that there were no significant differences between 
unoprostone and latanoprost in MD or PSD using the 
10-2 program (Humphrey Visual Field Analyzer), but after 
4 weeks of treatment, the MD of the unoprostone group, 
using frequency-doubling technology, was improved by 
1.7 dB over the pretreatment value.9 In patients with NTG, 
no prospective studies comparing the effects of unoprostone 
with other drugs have been reported.













Figure 3 Survival curve of visual field nonprogression in GPA.
Notes: (A) The cumulative probability of visual field nonprogression when the end point was defined as the time of “possible progression” in GPA. (B) The cumulative 
probability of visual field nonprogression when the end point was defined as the time of “highly possible progression” in GPA.
Abbreviations: gPa, guided progression analysis; laT, latanoprost; UnO, unoprostone.
Table 2 Analysis of the rate of nonprogression of visual field loss
Progression end point Cumulative survival rates after 3 years (%)
UNO group LAT group p-value
MD criteria 74 (55–94) 80 (63–98) 0.68
PsD criteria 94 (83–100) 90 (77–100) 0.61
Hemi-visual field TD criteria 77 (57–100) 70 (50–96) 0.59
“Possible progression” in GPA 67 (45–89) 49 (26–73) 0.21
“Highly possible progression” in GPA 94 (83–100) 75 (54–96) 0.13
TD criteria in each sector
1 94 (83–100) 81 (64–98) 0.22
2 82 (64–100) 67 (47–87) 0.22
3 83 (66–100) 95 (87–96) 0.22
4 100 (83–100) 95 (85–100) 0.36
5 72 (53–91) 86 (71–100) 0.35
6 61 (39–83) 80 (63–97) 0.21
Notes: garway–heath sector format15 was adopted as a division of the visual field. Each sector is described as follows: Sector 1, papillo-macular nerve fiber bundle area; 
Sector 2, upper inner arcuate nerve fiber bundle area; Sector 3, upper outer arcuate nerve fiber bundle area; Sector 4, nasal radial nerve fiber bundle area; Sector 5, under 
inner arcuate nerve fiber bundle area; Sector 6, under outer arcuate nerve fiber bundle area. The values in parentheses are the 95% CI. p-values were obtained with the 
log-rank test.
Abbreviations: gPa, guided progression analysis; laT, latanoprost; MD, mean deviation; PsD, pattern standard deviation; TD, total deviation; UnO, unoprostone.





Isopropyl unoprostone was developed in Japan in 1994 
as the world’s first prostaglandin-related drug and was 
reported to lower the IOP to a similar degree as timolol in 
patients with either POAG or ocular hypertension.19 Later, 
several prostaglandin-related drugs, including latanoprost, 
were launched and found to reduce IOP even more strongly 
than conventional products, including unoprostone. Such 
prostaglandin analogues are now the first-choice drugs in 
glaucoma therapy.
We conducted a 3-year comparative study in patients with 
NTG who received either unoprostone or latanoprost alone. 
Not only did we investigate the effects of the drugs on IOP, 
but we also focused on visual field loss progression.
Latanoprost conferred a significantly greater reduction in 
IOP than unoprostone after 3 years of treatment. Our study 
Table 3 hrT-ii changes
Stereometric parameter UNO group LAT group p-value
Cup area (mm2)
Before treatment 0.97±0.52 1.00±0.54 0.85
Final visit 0.87±0.45 0.96±0.44 0.55
rim area (mm2)
Before treatment 1.06±0.39 1.01±0.25 0.46
Final visit 1.16±0.36 1.04±0.41 0.09
Cup/disc area ratio
Before treatment 0.46±0.20 0.47±0.14 0.82
Final visit 0.41±0.18 0.47±0.14 0.29
Cup volume (mm3)
Before treatment 0.24±0.17 0.20±0.14 0.55
Final visit 0.22±0.16 0.21±0.16 0.97
rim volume (mm3)
Before treatment 0.26±0.13 0.24±0.12 0.51
Final visit 0.29±0.12 0.25±0.16 0.12
Notes: Values are mean ± SD. There were no significant differences between the 
groups. Data were analyzed with Mann–Whitney U test.
Abbreviations: hrT-ii, heidelberg retina Tomograph ii; laT, latanoprost; UnO, 
unoprostone.
Table 4 Patient dropouts
Reason for dropout UNO group (24 patients) LAT group (24 patients)
adverse reactions
Superficial keratitis 1 (9 months) 1 (15 months)
irritation 1 (6 months) 0
hyperemia 1 (3 months) 0
Discontinuation of hospital visit 1 (3 months) 2 (30 months, 33 months)
Cataract surgery 0 1 (33 months)
Pregnancy 0 1 (18 months)
Death 1 (15 months) 0
Change of therapya 2 (15 months, 27 months) 0
Change of the drug used in the other eye 0 1 (33 months)
The total number of patient dropouts 7 6
Notes: aInvestigator’s decision to decrease IOP. Dates in parentheses denote dropout time. The groups did not differ significantly in terms of the total number of patient 
dropouts (p=0.50). The groups did not differ significantly in terms of the number of patient dropouts because of adverse reactions (p=0.30) or change of therapy (p=0.49). 
Data were analyzed with Fisher’s exact probability test.
Abbreviations: iOP, intraocular pressure; laT, latanoprost; UnO, unoprostone.
period of 3 years is the longest among all of the reports 
mentioned so far,5–8,18 all of which compared IOP reduction 
between groups for a period of 8–12 weeks.
Additionally, Sponsel et al were the only other investiga-
tors to compare the groups in terms of visual field changes.9 
Their prospective study with a 4-week observation period 
seemed too short to detect visual field changes. To detect 
visual field changes reliably, we used not only MD, but also 
PSD, TD of the upper or lower hemi-visual field, GPA, and 
TD by sector, all of which can be indicators of local visual 
field deterioration. There were no significant differences 
between the groups with regard to any of these indices. 
We also investigated structural changes of the optic nerve 
head using a fundus photograph and the HRT-II. However, 
no significant differences were found between groups.
The “Collaborative NTG study”1,2 demonstrated that 
IOP reduction prevented visual field progression, even when 
the baseline IOP was in the normal range (NTG). Our 
present study demonstrated that unoprostone may have 
effects comparable to latanoprost in preventing the visual 
field loss, even though the IOP reduction was significantly 
weaker in the Unoprostone group than in the Latanoprost 
group. Thus, it implies that unoprostone may prevent visual 
field deterioration not only by lowering the IOP but also 
by improving optic nerve blood flow or providing neuro-
protection. As unoprostone has an extremely low affinity 
for prostaglandin F2α (FP) receptors, its pharmacological 
action is unclear. Nonetheless, many studies have addressed 
the various functions of unoprostone, such as its ability to 
improve blood circulation and protect neurons. Sugiyama and 
Azuma reported that subconjunctival injection of unoprostone 
into rabbit eyes inhibited the decrease of optic disc blood flow 
induced by intravitreal injection of endothelin-1.20 Moreover, 
Cuppoletti et al reported that unoprostone relaxes vascular 
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smooth muscle cells,11 and Kimura et al showed that unopro-
stone increases blood flow to the optic nerve head.13 Thieme 
et al demonstrated that unoprostone opens membrane Big 
Potassium (BK) channels (Ca2+-activated Maxi-K channels) 
and inhibits the elevation of intracellular Ca2+ concentration 
induced by endothelin-1.10 Unoprostone inhibits cell contrac-
tion of the trabecular meshwork and thus causes an increase 
in conventional outflow, which results in a decrease in IOP, 
as shown by Toris et al.12 Furthermore, Melamed showed that 
unoprostone inhibits cell apoptosis by acting on retinal gan-
glion cells, which implies a direct neuroprotective effect.21
Our study has several limitations, including a relatively 
small sample size, even though it was a randomized prospec-
tive study with a long-term observation period. However, 
even if the sample size were larger, unoprostone may not 
be found to be worse than latanoprost in terms of the visual 
field, because unoprostone showed comparable survival rates 
to latanoprost on all visual field criteria. Another limitation 
was the blinding procedures. Ideally, both investigators and 
patients should be blinded to the treatment groups by using the 
same eye drop bottles and the same number of instillations. 
In our study, although examinations including IOP measure-
ments were performed in a masked fashion, the investigators 
and patients were not blinded as to the treatment groups, which 
may have affected decisions regarding treatment alteration.
In conclusion, our present study demonstrated that 
although unoprostone reduced the IOP less than latanoprost 
in eyes with NTG, there were no significant differences in 
visual field loss progression between the two groups. This 
suggests that unoprostone may preserve the visual field to 
the same degree as latanoprost. Unoprostone may play a 
significant role in preventing visual field deterioration not 
only by lowering the IOP but also by other factors, such as 
improving optic nerve blood flow or neuroprotection.
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